ST Biology (000504.SZ) is planning to acquire a 51% stake in Huize Pharmaceutical, which is expected to constitute a major asset restructuring.

Wisdom Financial News APP News, *ST Biology (000504.SZ) announced that the company is planning to acquire 51% equity of Hunan Huize Biomedical Technology Co., Ltd. (hereinafter referred to as "Huize Medicine" or the "target company") in cash. After the completion of this transaction, Huize Medicine will become a controlling subsidiary of the company and be included in the consolidated financial statements. According to preliminary calculations, this transaction is expected to constitute a major asset restructuring as stipulated in the "Regulations on Major Asset Restructuring of Listed Companies".